Clinical Trials Browser

Rectal Neoplasms

NCT05356897 2024-09-19

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05900648 2024-04-29

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02682485 2023-04-26

SES-DTA

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms, Anastomotic Leak

NCT00936832 2022-08-30

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT04418895 2021-11-10

Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms

NCT04620473 2021-09-28

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms

NCT01915472 2021-08-19

A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT00002664 2017-07-13

Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01095523 2017-07-02

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

Phase 2 Withdrawn

GastrointestinalGynecologic

Colonic Neoplasms, Neoplasm Metastasis, Peritoneal Neoplasms, Rectal Neoplasms, Recurrence, Colorectal Neoplasms

NCT00408772 2017-06-09

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT01270438 2017-04-04

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT02046538 2017-01-25

Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT02586610 2017-01-20

Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms

NCT02287727 2016-10-12

Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms

NCT00571740 2016-07-06

Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02235324 2015-05-06

Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01659424 2014-12-18

HDRBT

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms

NCT00003786 2014-03-07

Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00118105 2013-01-03

S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00070434 2012-06-07

S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT00346099 2008-01-07

Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Clinical Trials

Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

SES-DTA

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer

Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer

Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer

Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment

Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer

HDRBT

Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer

S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer

S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum

Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum